However, the phase III trial of the PDH inhibitor devimistat was terminated prematurely due to ineffectiveness, which is related to AML cells compensating for PDH inhibition through gluconeogenesis [151]. The gene discussed is PDP1; the disease is acute myeloid leukemia.